Expertise in
18
conditions

Dr. Deborah Stephens

Internal Medicine
UNC Hospitals Pulmonary Function Lab
101 Manning Dr, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Expertise in
18
conditions
UNC Hospitals Pulmonary Function Lab
101 Manning Dr, 
Chapel Hill, NC 

Overview

Deborah Stephens is an Internal Medicine provider practicing medicine in Chapel Hill, North Carolina.

Dr. Stephens is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 119 peer reviewed articles and participating in 17 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in UT

Hospital Affiliations

Unc Hospitals

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UNC Hospitals Pulmonary Function Lab
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Phase II Study of the Efficacy of the Pneumococcal Pneumonia Vaccine Series in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency (PROTECT CLL)
Phase II Study of the Efficacy of the Pneumococcal Pneumonia Vaccine Series in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency (PROTECT CLL)
Enrollment Status: Recruiting
Publish Date: April 09, 2026
Intervention Type: Biological
Study Drugs: Pneumococcal 13-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Study Phase: Phase 2
Randomized Phase 2 Studying the Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)
Randomized Phase 2 Studying the Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)
Enrollment Status: Recruiting
Publish Date: December 03, 2025
Intervention Type: Drug
Study Drug: Nicotinamide
Study Phase: Phase 2
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Enrollment Status: Completed
Publish Date: June 10, 2026
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Acalabrutinib, Rituximab, Lenalidomide
Study Phase: Phase 1/Phase 2
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: TAA-T cells, Nivolumab
Study Phase: Phase 1
View 8 Less Clinical Trials

119 Total Publications

Active treatment in high-risk, early-stage CLL or SLL.
Active treatment in high-risk, early-stage CLL or SLL.
Journal: Clinical advances in hematology & oncology : H&O
Published: June 12, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Shreyaskumar Patel
Internal Medicine
Expertise in
26
conditions
Dr. Shreyaskumar Patel
Internal Medicine

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (19.7 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shreyaskumar Patel is an Internal Medicine provider practicing medicine in Cary, North Carolina. Dr. Patel is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Alveolar Soft Part Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Osteotomy.

Expertise in
22
conditions
Dr. Jan Burger
Internal Medicine
Expertise in
22
conditions
Dr. Jan Burger
Internal Medicine

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (19.7 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jan Burger is an Internal Medicine provider practicing medicine in Cary, North Carolina. Dr. Burger is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Angioplasty.

Expertise in
21
conditions
Dr. Christopher Dittus
Internal Medicine
Expertise in
21
conditions
Dr. Christopher Dittus
Internal Medicine

UNC Hospitals Pulmonary Function Lab

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
984-974-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christopher Dittus is an Internal Medicine provider practicing medicine in Chapel Hill, North Carolina. Dr. Dittus is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Deborah Stephens

How do I make an appointment with Dr. Deborah Stephens?

You can book an appointment with Dr. Deborah Stephens by calling their office at 919-966-4431. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Deborah Stephens a top-rated expert for Chronic B-Cell Leukemia (CBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Deborah Stephens is classified as an Elite expert for Chronic B-Cell Leukemia (CBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Deborah Stephens specialize in?

While Dr. Deborah Stephens is a Internal Medicine, they have specific expertise in Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Small Lymphocytic Lymphoma (SLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Deborah Stephens participate in research or clinical trials?

Yes. Dr. Deborah Stephens has published 119 articles and abstracts on conditions like Chronic B-Cell Leukemia (CBCL). You can view a list of Dr. Deborah Stephens's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Deborah Stephens accept my insurance?

Dr. Deborah Stephens accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 919-966-4431 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stephens's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile